Search

Your search keyword '"Hassan A"' showing total 2,618 results

Search Constraints

Start Over You searched for: Author "Hassan A" Remove constraint Author: "Hassan A" Journal blood Remove constraint Journal: blood
2,618 results on '"Hassan A"'

Search Results

1. Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML

2. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank

3. Clinical and functional spectrum of RAC2-related immunodeficiency

4. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

6. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank

7. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency

10. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review

11. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study

13. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. 'the TOTAL Trial'

14. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease

15. Identification and Interpretation of Clinically Relevant Somatic Variants from Whole-Genome Sequencing Data

16. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease

17. Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

18. Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

19. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

20. Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia

21. The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

23. Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

27. Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

29. Two types of BCR interactions are positively selected during leukemia development in the Eβ-TCL1 transgenic mouse model of CLL

31. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

32. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

33. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

34. Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

37. Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

39. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma

40. Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

43. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

44. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

45. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

46. MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

47. Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

48. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

49. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

Catalog

Books, media, physical & digital resources